

Tassilo Volz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8675043/publications.pdf>

Version: 2024-02-01

47
papers

4,816
citations

159585

30
h-index

243625

44
g-index

48
all docs

48
docs citations

48
times ranked

4496
citing authors

#	ARTICLE	IF	CITATIONS
1	Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA. <i>Science</i> , 2014, 343, 1221-1228.	12.6	774
2	IFN- λ inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. <i>Journal of Clinical Investigation</i> , 2012, 122, 529-537.	8.2	492
3	Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. <i>Hepatology</i> , 2006, 44, 675-684.	7.3	403
4	Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. <i>Nature Biotechnology</i> , 2008, 26, 335-341.	17.5	369
5	The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. <i>Journal of Hepatology</i> , 2013, 58, 861-867.	3.7	286
6	Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation. <i>Hepatology</i> , 2012, 55, 685-694.	7.3	190
7	Impaired Intrahepatic Hepatitis B Virus Productivity Contributes to Low Viremia in Most HBeAg-Negative Patients. <i>Gastroenterology</i> , 2007, 133, 843-852.	1.3	178
8	Hepatitis B Virus Limits Response of Human Hepatocytes to Interferon- λ in Chimeric Mice. <i>Gastroenterology</i> , 2011, 140, 2074-2083.e2.	1.3	137
9	RGB marking facilitates multicolor clonal cell tracking. <i>Nature Medicine</i> , 2011, 17, 504-509.	30.7	134
10	Serum HBV pgRNA as a clinical marker for cccDNA activity. <i>Journal of Hepatology</i> , 2017, 66, 460-462.	3.7	133
11	Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody. <i>Nature Biotechnology</i> , 2015, 33, 549-554.	17.5	129
12	Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo. <i>Gut</i> , 2018, 67, 542-552.	12.1	125
13	Binding of hepatitis B virus to its cellular receptor alters the expression profile of genes of bile acid metabolism. <i>Hepatology</i> , 2014, 60, 1483-1493.	7.3	120
14	A novel orally available small molecule that inhibits hepatitis B virus expression. <i>Journal of Hepatology</i> , 2018, 68, 412-420.	3.7	109
15	Human liver chimeric mice as a new model of chronic hepatitis E virus infection and preclinical drug evaluation. <i>Journal of Hepatology</i> , 2016, 64, 1033-1040.	3.7	106
16	Hepatitis Delta co-infection in humanized mice leads to pronounced induction of innate immune responses in comparison to HBV mono-infection. <i>Journal of Hepatology</i> , 2015, 63, 346-353.	3.7	104
17	Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection. <i>Journal of Clinical Investigation</i> , 2017, 127, 3177-3188.	8.2	93
18	Efficacy of NVR 3-778, Alone and In Combination With Pegylated Interferon, vs Entecavir In uPA/SCID Mice With Humanized Livers and HBV Infection. <i>Gastroenterology</i> , 2018, 154, 652-662.e8.	1.3	82

#	ARTICLE	IF	CITATIONS
19	In vivo proliferation of hepadnavirus-infected hepatocytes induces loss of covalently closed circular DNA in mice. <i>Hepatology</i> , 2010, 52, 16-24.	7.3	76
20	Persistent hepatitis D virus mono-infection in humanized mice is efficiently converted by hepatitis B virus to a productive co-infection. <i>Journal of Hepatology</i> , 2014, 60, 538-544.	3.7	74
21	Immune cell responses are not required to induce substantial hepatitis B virus antigen decline during pegylated interferon-alpha administration. <i>Journal of Hepatology</i> , 2014, 60, 500-507.	3.7	68
22	Hepatitis delta virus persists during liver regeneration and is amplified through cell division both in vitro and in vivo. <i>Gut</i> , 2019, 68, 150-157.	12.1	65
23	Sequential Combination Therapy Leads to Biochemical and Histological Improvement Despite Low Ongoing Intrahepatic Hepatitis B virus Replication. <i>Antiviral Therapy</i> , 2008, 13, 57-66.	1.0	59
24	Virion half-life in chronic hepatitis B infection is strongly correlated with levels of viremia. <i>Hepatology</i> , 2008, 48, 1079-1086.	7.3	56
25	T cell receptor grafting allows virological control of hepatitis B virus infection. <i>Journal of Clinical Investigation</i> , 2019, 129, 2932-2945.	8.2	51
26	A Slow Maturation Process Renders Hepatitis B Virus Infectious. <i>Cell Host and Microbe</i> , 2016, 20, 25-35.	11.0	50
27	Multiplexing clonality: combining RGB marking and genetic barcoding. <i>Nucleic Acids Research</i> , 2014, 42, e56-e56.	14.5	49
28	Both interferon alpha and lambda can reduce all intrahepatic HDV infection markers in HBV/HDV infected humanized mice. <i>Scientific Reports</i> , 2017, 7, 3757.	3.3	47
29	Small Animal Model Systems for Studying Hepatitis B Virus Replication and Pathogenesis. <i>Seminars in Liver Disease</i> , 2006, 26, 181-191.	3.6	44
30	Therapeutic shutdown of HBV transcripts promotes reappearance of the SMC5/6 complex and silencing of the viral genome in vivo. <i>Gut</i> , 2022, 71, 372-381.	12.1	40
31	Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression. <i>Oncology Reports</i> , 2012, 28, 1077-1083.	2.6	34
32	Hepatitis Delta Virus Acts as an Immunogenic Adjuvant in Hepatitis B Virus-Infected Hepatocytes. <i>Cell Reports Medicine</i> , 2020, 1, 100060.	6.5	18
33	Matrix Conditions and KLF2-Dependent Induction of Heme Oxygenase-1 Modulate Inhibition of HCV Replication by Fluvastatin. <i>PLoS ONE</i> , 2014, 9, e96533.	2.5	17
34	Primary Human Hepatocytes from Metabolic-Disordered Children Recreate Highly Differentiated Liver-Tissue-Like Spheroids on Alginate Scaffolds. <i>Tissue Engineering - Part A</i> , 2012, 18, 1443-1453.	3.1	15
35	A humanized mouse model of liver fibrosis following expansion of transplanted hepatic stellate cells. <i>Laboratory Investigation</i> , 2018, 98, 525-536.	3.7	13
36	Strong Antiviral Activity of the New L-Hydroxycytidine Derivative, L-HYD4FC, In HBV-Infected Human Chimeric UPA/SCID Mice. <i>Antiviral Therapy</i> , 2012, 17, 623-631.	1.0	10

#	ARTICLE	IF	CITATIONS
37	Clinical establishment of a laboratory developed quantitative HDV PCR assay on the cobas6800 high-throughput system. JHEP Reports, 2021, 3, 100356.	4.9	10
38	Primary Human Hepatocytes Repopulate Livers of Mice After In Vitro Culturing and Lentiviral-Mediated Gene Transfer. Tissue Engineering - Part A, 2016, 22, 742-753.	3.1	9
39	Haem oxygenase-1 polymorphisms can affect HCV replication and treatment responses with different efficacy in humanized mice. Liver International, 2017, 37, 1128-1137.	3.9	8
40	Murine hepatocytes do not support persistence of Hepatitis D virus mono-infection in vivo. Liver International, 2021, 41, 410-419.	3.9	7
41	Multi-color RGB marking enables clonality assessment of liver tumors in a murine xenograft model. Oncotarget, 2017, 8, 115582-115595.	1.8	7
42	Strong Replication Interference Between Hepatitis Delta Viruses in Human Liver Chimeric Mice. Frontiers in Microbiology, 2021, 12, 671466.	3.5	5
43	PS-155-HBV entry inhibition after interferon alpha treatment hinders HBV rebound in hepatocytes that became negative for all HBV markers during interferon treatment. Journal of Hepatology, 2019, 70, e98.	3.7	4
44	Modeling infection with hepatitis B viruses in vivo. Future Virology, 2006, 1, 461-469.	1.8	0
45	Experimental Models: Cell Culture and Animal Models. Molecular and Translational Medicine, 2016, , 35-62.	0.4	0
46	FRI-134-Comparative analysis of intrahepatic and peripheral chemokine responses in chronic hepatitis B, C and D in vivo. Journal of Hepatology, 2019, 70, e446.	3.7	0
47	Therapeutic shutdown of HBV transcripts promotes reappearance of the SMC5/6 complex and cccDNA silencing in vivo without affecting posttranslational modifications of cccDNA-bound histones. Zeitschrift Fur Gastroenterologie, 2022, 60, .	0.5	0